STOCK TITAN

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
partnership

InterCure (NASDAQ: INCR) has expanded its strategic partnership with Cookies, a globally recognized cannabis brand, to Germany. The agreement allows InterCure to cultivate, manufacture, import, and distribute Cookies' branded products in 8 licensed pharmacies across Germany through Cookies Corners. This expansion follows their existing partnerships in the UK, Austria, and Israel.

InterCure will produce Cookies' products at its EU-GMP manufacturing sites, including future offerings like live resin, live rosin, and vapes. The partnership aims to capitalize on Germany's growing medical cannabis market, which saw a 400% increase in prescriptions from March to June 2024 following the passage of the 'CanG' Cannabis Act.

This collaboration combines Cookies' diverse portfolio of over 70 cannabis cultivars and 2,000 products with InterCure's established presence as a leading vertically integrated medical cannabis company outside North America.

InterCure (NASDAQ: INCR) ha ampliato la sua partnership strategica con Cookies, un marchio di cannabis riconosciuto a livello globale, per espandersi in Germania. L'accordo consente a InterCure di coltivare, produrre, importare e distribuire i prodotti a marchio Cookies in 8 farmacie autorizzate in tutta la Germania tramite Cookies Corners. Questa espansione segue le loro partnership esistenti nel Regno Unito, in Austria e in Israele.

InterCure produrrà i prodotti Cookies presso i suoi stabilimenti di produzione certificati EU-GMP, inclusi futuri prodotti come resina viva, rosin vivo e vaporizzatori. La partnership mira a capitalizzare la crescente domanda di cannabis medica in Germania, dove si è registrato un aumento del 400% delle prescrizioni da marzo a giugno 2024 dopo l'approvazione della legge 'CanG' sulla cannabis.

Questa collaborazione combina il portfolio diversificato di Cookies, con oltre 70 cultivar di cannabis e 2.000 prodotti, con la presenza consolidata di InterCure come leader nel settore della cannabis medica integrata verticalmente al di fuori del Nord America.

InterCure (NASDAQ: INCR) ha ampliado su asociación estratégica con Cookies, una marca de cannabis reconocida a nivel mundial, para expandirse en Alemania. El acuerdo permite a InterCure cultivar, fabricar, importar y distribuir los productos de marca Cookies en 8 farmacias licenciadas en toda Alemania a través de Cookies Corners. Esta expansión sigue a sus asociaciones existentes en el Reino Unido, Austria e Israel.

InterCure producirá los productos de Cookies en sus sitios de fabricación EU-GMP, incluyendo futuras ofertas como resina viva, rosin vivo y vaporizadores. La asociación busca capitalizar el creciente mercado de cannabis médico en Alemania, que vio un aumento del 400% en las recetas de marzo a junio de 2024, tras la aprobación de la Ley de Cannabis 'CanG'.

Esta colaboración combina el diverso portafolio de Cookies, con más de 70 cultivares de cannabis y 2.000 productos, con la presencia consolidada de InterCure como una de las principales empresas de cannabis médico integradas verticalmente fuera de América del Norte.

InterCure (NASDAQ: INCR)는 세계적으로 인정받는 대마초 브랜드 Cookies와의 전략적 파트너십을 독일로 확장했습니다. 이 계약은 InterCure가 8개의 라이센스 약국을 통해 Cookies Corners에서 Cookies 브랜드 제품을 재배, 제조, 수입 및 유통할 수 있도록 허용합니다. 이 확장은 영국, 오스트리아 및 이스라엘에서의 기존 파트너십에 이어 이루어졌습니다.

InterCure는 EU-GMP 제조 시설에서 Cookies의 제품을 생산할 것이며, 살아있는 수지, 라이브 로진 및 전자담배와 같은 향후 제품을 포함합니다. 이 파트너십은 'CanG' 대마초 법안 통과 이후 2024년 3월에서 6월 사이에 처방전이 400% 증가한 독일의 성장하는 의료 대마초 시장을 활용하는 것을 목표로 하고 있습니다.

이 협력은 Cookies의 70종 이상의 대마초 품종과 2,000개 제품의 다양한 포트폴리오를 InterCure의 북미 이외 지역에서 수직적으로 통합된 의료 대마초 기업으로서의 확립된 존재와 결합합니다.

InterCure (NASDAQ: INCR) a élargi son partenariat stratégique avec Cookies, une marque de cannabis reconnue mondialement, pour se développer en Allemagne. Cet accord permet à InterCure de cultiver, produire, importer et distribuer les produits de marque Cookies dans 8 pharmacies licenciées à travers l'Allemagne via Cookies Corners. Cette expansion fait suite à leurs partenariats existants au Royaume-Uni, en Autriche et en Israël.

InterCure produira les produits Cookies à ses sites de fabrication certifiés EU-GMP, y compris des offres futures telles que la résine vivante, le rosin vivant et les vapes. Le partenariat vise à tirer parti du marché croissant du cannabis médical en Allemagne, qui a connu une augmentation de 400% des prescriptions entre mars et juin 2024, suite à l'adoption de la loi 'CanG' sur le cannabis.

Cette collaboration combine le portefeuille diversifié de Cookies avec plus de 70 cultivars de cannabis et 2 000 produits avec la présence bien établie d'InterCure en tant que leader dans le domaine du cannabis médical intégré verticalement en dehors de l'Amérique du Nord.

InterCure (NASDAQ: INCR) hat seine strategische Partnerschaft mit Cookies, einer weltweit anerkannten Cannabis-Marke, auf Deutschland ausgeweitet. Die Vereinbarung ermöglicht es InterCure, die Markenprodukte von Cookies in 8 lizenzierten Apotheken in ganz Deutschland über Cookies Corners anzubauen, herzustellen, zu importieren und zu vertreiben. Diese Expansion folgt auf ihre bestehenden Partnerschaften im Vereinigten Königreich, in Österreich und in Israel.

InterCure wird die Produkte von Cookies an seinen EU-GMP-zertifizierten Produktionsstandorten herstellen, einschließlich zukünftiger Angebote wie Live Resin, Live Rosin und Vapes. Ziel der Partnerschaft ist es, vom wachsenden medizinischen Cannabis-Markt in Deutschland zu profitieren, der von März bis Juni 2024 einen 400%igen Anstieg der Verschreibungen nach Verabschiedung des 'CanG' Cannabis-Gesetzes verzeichnete.

Diese Zusammenarbeit kombiniert das vielfältige Portfolio von Cookies mit über 70 Cannabissorten und 2.000 Produkten mit der etablierten Präsenz von InterCure als führendes vertikal integriertes Unternehmen im Bereich medizinisches Cannabis außerhalb Nordamerikas.

Positive
  • Expansion into the German market, a key growth area for medical cannabis in Europe
  • Partnership with Cookies, a globally recognized and sought-after cannabis brand
  • Access to Cookies' diverse portfolio of over 70 cannabis cultivars and 2,000 products
  • Ability to produce and distribute Cookies' products through InterCure's EU-GMP manufacturing sites
  • Establishment of 8 licensed Cookies Corners pharmacies across Germany
  • Potential to capitalize on the 400% increase in German medical cannabis prescriptions from March to June 2024
Negative
  • None.

Insights

The expansion of InterCure's partnership with Cookies into Germany represents a significant move in the European cannabis market. With Germany's recent cannabis reform and the reported 400% increase in medical cannabis prescriptions, this strategic agreement is well-timed. The collaboration leverages InterCure's established infrastructure and Cookies' brand recognition, potentially positioning them as early leaders in the German market.

However, investors should consider that while the growth potential is substantial, the European cannabis market is still evolving. Regulatory changes and market acceptance will be critical factors to watch. The success of this venture will depend on how effectively InterCure can adapt Cookies' retail experience to German consumer preferences and navigate the country's regulatory landscape.

This strategic partnership expansion could have positive financial implications for InterCure. By leveraging Cookies' brand and genetics across multiple European markets, InterCure is diversifying its revenue streams and potentially increasing its market share. The agreement to operate 8 Cookies Corners in major German cities provides a clear path for revenue growth.

However, it's important to note that the financial impact will depend on factors such as operational costs, regulatory compliance expenses and market penetration rates. Investors should monitor upcoming financial reports to assess the actual revenue contribution and profitability of this expansion. While promising, it's important to remember that entering new markets often involves significant upfront investments before realizing returns.

The expansion of InterCure and Cookies' partnership into Germany is significant from a medical perspective. Germany's recent cannabis reform has led to a substantial increase in medical cannabis prescriptions, indicating growing acceptance and demand for cannabinoid therapeutics. InterCure's commitment to EU-GMP standards ensures high-quality, pharma-grade products for patients.

The introduction of Cookies' diverse genetic portfolio, including over 70 proprietary cannabis cultivars, could potentially offer German patients a wider range of treatment options. However, it's important to note that the medical efficacy of these products will need to be demonstrated through rigorous clinical research to gain widespread acceptance in the medical community. Investors should keep an eye on any upcoming clinical trials or research initiatives that could validate the therapeutic benefits of these products in the German market.

InterCure expands its European footprint to launch Cookies Corners licensed pharmacies in Germany alongside differentiated online platforms with the official cookies retail experience, enhancing branded product offerings with the most-recognized global cannabis brand.

NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)-- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outside of North America, is announcing a new strategic agreement with Cookies, the globally recognized cannabis brand, to cultivate, manufacture, import and distribute Cookies’ branded products, produced from its cultivation and manufacturing facilities, initially in 8 licensed branded pharmacies across Germany, through Cookies Corners. This agreement marks an expansion of InterCure and Cookies’ partnership footprint in Europe now covering the UK, Austria, and Germany, alongside strategic collaborations in Israel.

Under the terms of the new agreement, InterCure will cultivate, and manufacture Cookies licensed genetics and products at its global supply chain facilities. InterCure's EU-GMP manufacturing sites will import, register, and produce Cookies-branded products, including future range of next-generation offerings such as live resin and live rosin products and vapes. These products will be dispensed through InterCure's Cookies Corner licensed pharmacies and online platforms, differentiated by the official Cookies retail experience.

This agreement follows the passage of Germany's "CanG" Cannabis Act on April 1st, 2023. Notably, according to a recent report from Bloomwell Group, the number of medical cannabis prescriptions in Germany increased by 400 percent from March to June 2024, highlighting the significant impact of the new legislation on the market.1

Cookies is globally recognized as one of the most sought-after and best-selling cannabis brands, with a rapidly expanding international presence. Its diverse portfolio, featuring over 70 proprietary cannabis cultivars and more than 2,000 products, has established Cookies’ reputation for delivering premium quality to consumers worldwide. Drawing on the unique Cookies retail experience and cutting-edge genetics, along with InterCure's established reputation as the leading vertically integrated medical cannabis company outside North America operating over 25 pharmaceutical cannabis pharmacies, this partnership is set to deliver cannabinoid therapeutics that meet the most rigorous standards in some of the fastest-growing markets worldwide.

"We are excited to strengthen our partnership with Cookies and extend our reach into Germany, a pivotal market for medical cannabis in Europe," said Alexander Rabinovitch, CEO of InterCure. "This agreement enables us to introduce Cookies' globally renowned retail experience to the fast growing German market through Cookies Corners to be located in 8 major German cities advancing our commitment to providing access to high-quality, pharma-grade cannabis on a global scale. With Germany’s recent Cannabis reform, the European market is on the cusp of significant growth, and we look forward to making one of the world’s leading cannabis brands accessible to patients in Germany, Austria and the UK."

Parker Berling, President of Cookies, commented: "Our partnership with InterCure is opening new doors in Europe, and I’m especially excited to bring Cookies Corners to Germany, for the first time. The momentum around cannabis legalization here is truly groundbreaking and signals a new era for the entire continent. Berner’s connection to Germany goes beyond business—his music found an unexpected audience here, where he had the chance to experience the vibrant culture firsthand. With the UK also playing a pivotal role in the rise of California cannabis, we’re now set to bring our unique genetics and passion for quality to European patients through this collaboration.”

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

For more information, visit www.intercure.co.

About Cookies

Cookies is the most globally recognized cannabis company; founded in 2010 by Billboard-charting rapper and entrepreneur Berner and Bay Area breeder and cultivator Jai. The company creates game-changing genetics and offers a collection of over 70 proprietary cannabis cultivars and more than 2,000 products. Headquartered in San Francisco, the company is actively involved in advocacy and social impact initiatives to enrich communities disproportionately impacted by the War on Drugs. Cookies opened its first retail store in 2018 in Los Angeles, has since expanded to over 70 retail locations in over 20 markets across 6 countries, and was recently named one of America's Hottest Brands of 2021 by Ad Age; the first cannabis brand to ever receive this accolade.

To learn more about Cookies, visit cookies.co

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements may include, but are not limited to, the Company’s success of its global expansion plans, its expansion strategy to major markets worldwide, statements relating to the security events in Israel, as well as statements, other than historical facts, that address activities, events or developments that InterCure intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s success of its global expansion plans, its continued growth, the expected operations, financial results business strategy, competitive strengths, goals and expansion and growth plans, expansion strategy to major markets worldwide, the impact of the COVID-19 pandemic, the impact of the war in Israel and the war in Ukraine and the conditions of the markets generally. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. regulatory landscapes and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, and reliance on the expertise and judgment of our senior management. More detailed information about the risks and uncertainties affecting us is contained under the heading "Risk Factors" included in the Company's most recent Annual Report on Form 20-F and in other filings that we have made and may make with the Securities and Exchange Commission in the future.

______________________________
1 https://businessofcannabis.com/new-report-on-germanys-medical-cannabis-market-indicates-that-german-market-is-prepared-for-rapid-growth

InterCure Ltd.

Amos Cohen, Chief Financial Officer

amos@intercure.co

Source: InterCure

FAQ

What is the new strategic agreement between InterCure (INCR) and Cookies in Germany?

InterCure has partnered with Cookies to cultivate, manufacture, import, and distribute Cookies' branded products in 8 licensed pharmacies across Germany through Cookies Corners. This expands their existing partnership to include Germany alongside the UK, Austria, and Israel.

How many Cookies Corners licensed pharmacies will InterCure (INCR) open in Germany?

InterCure plans to open 8 Cookies Corners licensed pharmacies across major German cities as part of their expansion into the German market.

What products will InterCure (INCR) manufacture and distribute under the Cookies brand in Germany?

InterCure will produce Cookies' licensed genetics and products, including future offerings such as live resin, live rosin products, and vapes, at its EU-GMP manufacturing sites for distribution in Germany.

How has the German medical cannabis market changed since the 'CanG' Cannabis Act?

According to a report from Bloomwell Group, the number of medical cannabis prescriptions in Germany increased by 400% from March to June 2024, following the passage of the 'CanG' Cannabis Act on April 1st, 2023.

Intercure Ltd. Ordinary Shares

NASDAQ:INCR

INCR Rankings

INCR Latest News

INCR Stock Data

60.87M
27.64M
39.6%
11.57%
0.03%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Herzliya